ClinicalTrials.gg
CompletedNCT04557306Updated Apr 8, 2024

Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer

A Phase 1 interventional study of CBT101 cells, every 2 weeks and CBT101 cells, every 4 weeks in Solid Tumor, sponsored by CHABiotech CO., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by CHABiotech CO., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Study summary

The objective of the study is to evaluate tolerability and safety of CBT101 in patients who underwent curative surgery and adjuvant therapy for solid cancer

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

CHABiotech CO., Ltd is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female adults aged 19 years and older
  2. Patients with solid tumors as below (1) or cytologically confirmed solid tumors (2) 4 - 12 weeks of last therapy after radical operations and adjuvant therapy
  3. 6 months
  4. perfornace status (ECOG PS) 0-1

Exclusion criteria

Exclusion Criteria:

  1. History of or spinal cord compression
  2. History of peritoneal carninomatosis
  3. Hemoglobine less than 9.0g/dL
  4. (ANC) less than 1.5x10\^3/mm\^3
  5. count less than 75x10\^9/L
  6. Total bilitbinn grater than 1.5 times te
  7. Alanine amino transferase () greater than 3 times the upper limit of normal
  8. Alanine phospatase (ALP) greater than 2.5 times the upper limit of normal
  9. Uncontrolled hypertension
  10. Intensive insuline therapy
  11. Active infectious disease
  12. Patients with history or allergy to product
  13. Pregmant of lactating woman
  14. Patients who have participated in another clinical trials witin 30 days before the start of this clinical trial
  15. Patients judged to be inappropriate for this study by the investigator with other reasons
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    CBT101 q2w

    CBT101 cells, every 2 weeks

    Biological: CBT101 cells, every 2 weeks

  • Experimental
    CBT101 q4w

    CBT101 cells, every 4 weeks

    Biological: CBT101 cells, every 4 weeks

Interventions

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    Dose limiting toxicity (DLT)

    Time frame: 29 days

Secondary outcomes

  1. Disease-free survival rate (DFS)

    Disease-free survival rate (DFS)

    Time frame: 6 months

  2. Oerall survival rate (OS)

    Oerall survival rate (OS)

    Time frame: 6 months

07

Study locations

1 site
  • CHA Bundang Medical Center
    Seongnam-si, Gyeonggi-do 13496, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Oct 2021, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2020
First posted
Sep 21, 2020
StartActual
Sep 21, 2020
Primary completionActual
Oct 26, 2021
CompletionActual
Oct 26, 2021
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04557306
Lead sponsor
CHABiotech CO., Ltd
Responsible party
Sponsor
First posted
Sep 21, 2020
Start date
Sep 21, 2020
Primary completion
Oct 26, 2021
Completion
Oct 26, 2021
Last update
Apr 8, 2024

Study contacts

Chan Kim
principal investigator · CHA Bundang Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vebreltinib

Start the discussion